

ESTTA Tracking number: **ESTTA998064**

Filing date: **08/28/2019**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Notice of Opposition

Notice is hereby given that the following party opposes registration of the indicated application.

Opposer Information

Name	Neurocrine Biosciences, Inc.
Granted to Date of previous extension	08/28/2019
Address	12780 EL CAMINO REAL SAN DIEGO, CA 92130 UNITED STATES

Attorney information	David Donahue FROSS ZELNICK LEHRMAN & ZISSU. P.C. 151 West 42nd Street 17th Floor NEW YORK, NY 10036 UNITED STATES ddonahue@fzlj.com, ttabfiling@fzlj.com 212-813-5900
----------------------	--

Applicant Information

Application No	88234933	Publication date	04/30/2019
Opposition Filing Date	08/28/2019	Opposition Period Ends	08/28/2019
Applicant	FNM CORPORATION LTD 27 Old Gloucester street London WC1N 3AX, WC1N3AX UNITED KINGDOM		

Goods/Services Affected by Opposition

<p>Class 005. First Use: 0 First Use In Commerce: 0 All goods and services in the class are opposed, namely: Non-antibiotic Pharmaceutical preparation for skin care; Non-antibiotic Pharmaceutical preparation for the treatment of gout; Non-antibiotic pharmaceutical preparations acting on the central nervous system; Non-antibiotic Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Non-antibiotic pharmaceutical preparations for the treatment of itch, pain, neuropathy and inflammation in humans or animals by cooling the skin; Non-antibiotic Pharmaceutical preparations for treating allergies; Non-antibiotic Pharmaceutical preparations for treating hypertension; Non-antibiotic Pharmaceutical preparations for treating skin disorders; Non-antibiotic Pharmaceutical preparations for treating sunburn; Non-antibiotic Pharmaceutical preparations for use in chemotherapy; Non-antibiotic Pharmaceutical preparations for use in dermatology; Non-antibiotic Pharmaceutical products and preparations against dry skin and blemishes caused by pregnancy; Non-antibiotic pharmaceutical preparations for the treatment of itch, pain, neuropathy and inflammation related to diabetes, chemotherapy, radiotherapy, neuro-dermatitis, chickenpox, shingles, atopic dermatitis, eczema, psoriasis, urticaria (hives), multiple sclerosis, sciatica, migraine, sunburn, scars, varicose veins and skin rashes in humans or animals,</p>


all by cooling the skin; all the above-mentioned supplied in aerosol form


Grounds for Opposition

Priority and likelihood of confusion

Trademark Act Section 2(d)

Marks Cited by Opposer as Basis for Opposition

U.S. Registration No.	5762522	Application Date	10/15/2018
Registration Date	05/28/2019	Foreign Priority Date	NONE
Word Mark	NEUROCRINE		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 042. First use: First Use: 1995/01/00 First Use In Commerce: 1995/01/00 Research and development services in the fields of pharmaceuticals and bio-technology		

U.S. Registration No.	5762521	Application Date	10/15/2018
Registration Date	05/28/2019	Foreign Priority Date	NONE
Word Mark	NEUROCRINE		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 005. First use: First Use: 2017/04/26 First Use In Commerce: 2017/04/26 Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders; Pharmaceutical preparations for the treatment of tardive dyskinesia		

U.S. Registration	2691306	Application Date	08/24/1999
-------------------	---------	------------------	------------

No.			
Registration Date	02/25/2003	Foreign Priority Date	NONE
Word Mark	NEUROCRINE BIOSCIENCES		
Design Mark	NEUROCRINE BIOSCIENCES		
Description of Mark	NONE		
Goods/Services	Class 005. First use: First Use: 2001/06/05 First Use In Commerce: 2001/06/05 pharmaceutical preparations for the treatment of [cancer and] neurological, endocrinological, and central nervous system disorders and diseases		

U.S. Registration No.	2669550	Application Date	08/24/1999
Registration Date	12/31/2002	Foreign Priority Date	NONE
Word Mark	NEUROCRINE BIOSCIENCES		
Design Mark	NEUROCRINE BIOSCIENCES		
Description of Mark	NONE		
Goods/Services	Class 042. First use: First Use: 1995/01/00 First Use In Commerce: 1995/01/00 research and development services in the field of pharmaceuticals and treatments for cancer and neurological, endocrinological, and central nervous system disorders and diseases		

Attachments	88155436#TMSN.png(bytes) 88155421#TMSN.png(bytes) 75783702#TMSN.png(bytes) 75783701#TMSN.png(bytes) F3180059.PDF(155119 bytes)
-------------	---

Signature	/David Donahue/
Name	David Donahue
Date	08/28/2019

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

NEUROCRINE BIOSCIENCES, INC.,

Opposer,

-against-

FNM CORPORATION LTD, TA
FRANCEMED PHARMA,

Applicant.

NOTICE OF OPPOSITION

Opposer, Neurocrine Biosciences, Inc., a corporation organized under the laws of Delaware and having an office and principal place of business in San Diego, California (“Opposer”), believes that it would be damaged by the registration of the trademark NEUROCRINE applied for in Application Serial No. 88/234,933, filed on December 19, 2018, for goods in International Class 5 by FNM CORPORATION LTD, TA FRANCEMED PHARMA (“Applicant”). As grounds for the opposition, Opposer alleges as follows:

1. Opposer is a biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed disorders.
2. For many years, Opposer has used the NEUROCRINE trademark and variants thereof (collectively, the “NEUROCRINE Marks”) in the United States for pharmaceutical preparations and for research and development services in the fields of pharmaceuticals and biotechnology.
3. As a result of Opposer’s reputation, use and substantial sales success, including for example sales exceeding \$180 million in the second quarter of 2019 alone, the NEUROCRINE Marks have become strong trademarks identifying Opposer’s products and services exclusively.

As such, the NEUROCRINE Marks represent enormous goodwill and are extremely valuable assets of Opposer.

4. In addition, Opposer owns the following U.S. Trademark Registrations for the NEUROCRINE Marks:

- U.S. Reg. No. 5,762,522 for the NEUROCRINE mark for “Research and development services in the fields of pharmaceuticals and biotechnology” in International Class 42;
- U.S. Reg. No. 5,762,521 for the NEUROCRINE mark for “Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders; Pharmaceutical preparations for the treatment of tardive dyskinesia” in International Class 5;
- U.S. Reg. No. 2,691,306 for the NEUROCRINE BIOSCIENCES mark for “pharmaceutical preparations for the treatment of neurological, endocrinological, and central nervous system disorders and diseases” in International Class 5; and
- U.S. Reg. No. 2,669,550 for the NEUROCRINE BIOSCIENCES mark for “research and development services in the field of pharmaceuticals and treatments for cancer and neurological, endocrinological, and central nervous system disorders and diseases” in International Class 42.

(collectively, “Opposer’s Registrations”). Printouts from the Trademark Status & Document Retrieval (TSDR) database showing the current status and title of Opposer’s Registrations are attached as Exhibit 1.

5. Each of Opposer’s Registrations is valid, subsisting and in full effect and serves as prima facie evidence of the validity of the identified mark and of Opposer’s exclusive right to use the identified mark in connection with the goods and services identified therein, pursuant to Section 33(b) of the Lanham Act, 15 U.S.C. § 1115(a). Additionally, Reg. Nos. 2,669,550 and

2,691,306 have become incontestable pursuant to Section 15 of the Lanham Act, 15 U.S.C. § 1065.

6. Upon information and belief, Applicant is a limited liability company organized under the laws of the United Kingdom with a place of business in London, United Kingdom.

7. On December 19, 2018, Applicant filed Application Serial No. 88/234,933 to register the mark NEUROCURE for the following goods in International Class 5 based on Applicant's purported intention to use the mark pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051(b):

Non-antibiotic Pharmaceutical preparation for skin care; Non-antibiotic Pharmaceutical preparation for the treatment of gout; Non-antibiotic pharmaceutical preparations acting on the central nervous system; Non-antibiotic Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Non-antibiotic pharmaceutical preparations for the treatment of itch, pain, neuropathy and inflammation in humans or animals by cooling the skin; Non-antibiotic Pharmaceutical preparations for treating allergies; Non-antibiotic Pharmaceutical preparations for treating hypertension; Non-antibiotic Pharmaceutical preparations for treating skin disorders; Non-antibiotic Pharmaceutical preparations for treating sunburn; Non-antibiotic Pharmaceutical preparations for use in chemotherapy; Non-antibiotic Pharmaceutical preparations for use in dermatology; Non-antibiotic Pharmaceutical products and preparations against dry skin and blemishes caused by pregnancy; Non-antibiotic pharmaceutical preparations for the treatment of itch, pain, neuropathy and inflammation related to diabetes, chemotherapy, radiotherapy, neuro-dermatitis, chickenpox, shingles, atopic dermatitis, eczema, psoriasis, urticaria (hives), multiple sclerosis, sciatica, migraine, sunburn, scars, varicose veins and skin rashes in humans or animals, all by cooling the skin; all the above-mentioned supplied in aerosol form.

8. Opposer's rights in the NEUROCRINE Marks are prior and superior to any rights Applicant may claim in NEUROCURE.

9. Registration of NEUROCURE to Applicant would be inconsistent with Opposer's prior rights and statutory grant of exclusivity of use.

10. NEUROCURE is confusingly similar to Opposer's prior-used and prior-registered NEUROCRINE Marks. The marks of the parties are confusingly similar in sight, sound, and

commercial impressions. Applicant's use and registration of the mark NEUROCURE in connection with the goods identified in its application, which are closely related to Opposer's goods and services, is likely to cause confusion, cause mistake or to deceive consumers to falsely believe that Applicant's goods emanate from or otherwise are authorized, sponsored by, or affiliated with Opposer, in violation of Section 2(d) of the Lanham Act, 15 U.S.C. § 1052(d).

11. By reason of the foregoing, Opposer will be harmed by registration of Applicant's NEUROCURE mark.

WHEREFORE, it is respectfully requested that this opposition be sustained and that the registration sought by Application Serial No. 88/234,933 be denied.

Dated: August 28, 2019
New York, New York

FROSS ZELNICK LEHRMAN & ZISSU, P.C.

By: /David Donahue/
David Donahue (ddonahue@fzlj.com)
151 West 42nd Street, 17th Floor
New York, New York 10036
(212) 813-5900

Attorneys for Opposer

EXHIBIT 1

Generated on: This page was generated by TSDR on 2019-08-28 10:09:43 EDT

Mark: NEUROCRINE

NEUROCRINE

US Serial Number: 88155436

Application Filing Date: Oct. 15, 2018

US Registration Number: 5762522

Registration Date: May 28, 2019

Filed as TEAS RF: Yes

Currently TEAS RF: Yes

Register: Principal

Mark Type: Service Mark

Status: Registered. The registration date is used to determine when post-registration maintenance documents are due.

Status Date: May 28, 2019

Publication Date: Mar. 12, 2019

Mark Information

Mark Literal Elements: NEUROCRINE

Standard Character Claim: Yes. The mark consists of standard characters without claim to any particular font style, size, or color.

Mark Drawing Type: 4 - STANDARD CHARACTER MARK

Related Properties Information

International Registration Number: 1468022

International Application(s) /Registration(s) Based on this Property: A0085047, A0085061/1468022

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis (..) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: Research and development services in the fields of pharmaceuticals and biotechnology

International Class(es): 042 - Primary Class

U.S Class(es): 100, 101

Class Status: ACTIVE

Basis: 1(a)

First Use: Jan. 1995

Use in Commerce: Jan. 1995

Basis Information (Case Level)

Filed Use: Yes

Currently Use: Yes

Amended Use: No

Filed ITU: No

Currently ITU: No

Amended ITU: No

Filed 44D: No

Currently 44D: No

Amended 44D: No

Filed 44E: No

Currently 44E: No

Amended 44E: No

Filed 66A: No

Currently 66A: No

Filed No Basis: No

Currently No Basis: No

Current Owner(s) Information

Owner Name: Neurocrine Biosciences, Inc.

Owner Address: 12780 El Camino Real
San Diego, CALIFORNIA 92130
UNITED STATES

Legal Entity Type: CORPORATION

State or Country DELAWARE
Where Organized:

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Allison Strickland Ricketts

Docket Number: NEUB 1811028

Correspondent

Correspondent Name/Address: ALLISON STRICKLAND RICKETTS
FROSS ZELNICK LEHRMAN & ZISSU, P.C.
4 TIMES SQUARE, 17TH FLOOR
NEW YORK, NEW YORK 10036
UNITED STATES

Phone: 212-813-5967

Correspondent e-mail: ricketts-docket@fzlz.com

Correspondent e-mail Authorized: Yes

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
May 28, 2019	REGISTERED-PRINCIPAL REGISTER	
Mar. 12, 2019	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	
Mar. 12, 2019	PUBLISHED FOR OPPOSITION	
Feb. 20, 2019	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	
Jan. 31, 2019	APPROVED FOR PUB - PRINCIPAL REGISTER	
Jan. 24, 2019	ASSIGNED TO EXAMINER	91238
Oct. 25, 2018	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	
Oct. 18, 2018	NEW APPLICATION ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: PUBLICATION AND ISSUE SECTION

Date in Location: May 28, 2019

Generated on: This page was generated by TSDR on 2019-08-28 10:10:05 EDT

Mark: NEUROCRINE

NEUROCRINE

US Serial Number: 88155421

Application Filing Date: Oct. 15, 2018

US Registration Number: 5762521

Registration Date: May 28, 2019

Filed as TEAS RF: Yes

Currently TEAS RF: Yes

Register: Principal

Mark Type: Trademark

TM5 Common Status Descriptor:



LIVE/REGISTRATION/Issued and Active

The trademark application has been registered with the Office.

Status: Registered. The registration date is used to determine when post-registration maintenance documents are due.

Status Date: May 28, 2019

Publication Date: Mar. 12, 2019

Mark Information

Mark Literal Elements: NEUROCRINE

Standard Character Claim: Yes. The mark consists of standard characters without claim to any particular font style, size, or color.

Mark Drawing Type: 4 - STANDARD CHARACTER MARK

Related Properties Information

International Registration Number: 1468022

International Application(s) /Registration(s) Based on this Property: A0085047, A0085061/1468022

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders; Pharmaceutical preparations for the treatment of tardive dyskinesia

International Class(es): 005 - Primary Class

U.S Class(es): 006, 018, 044, 046, 051, 052

Class Status: ACTIVE

Basis: 1(a)

First Use: Apr. 26, 2017

Use in Commerce: Apr. 26, 2017

Basis Information (Case Level)

Filed Use: Yes
Filed ITU: No
Filed 44D: No
Filed 44E: No
Filed 66A: No
Filed No Basis: No

Currently Use: Yes
Currently ITU: No
Currently 44E: No
Currently 66A: No
Currently No Basis: No

Current Owner(s) Information

Owner Name: Neurocrine Biosciences, Inc.
Owner Address: 12780 El Camino Real
San Diego, CALIFORNIA UNITED STATES 92130
Legal Entity Type: CORPORATION
State or Country Where Organized: DELAWARE

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Allison Strickland Ricketts
Docket Number: NEUB 1811040

Correspondent

Correspondent Name/Address: ALLISON STRICKLAND RICKETTS
FROSS ZELNICK LEHRMAN & ZISSU, P.C.
4 TIMES SQUARE, 17TH FLOOR
NEW YORK, NEW YORK UNITED STATES 10036

Phone: 212-813-5967

Correspondent e-mail: ricketts-docket@fzlz.com

Correspondent e-mail Authorized: Yes

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
May 28, 2019	REGISTERED-PRINCIPAL REGISTER	
Mar. 12, 2019	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	
Mar. 12, 2019	PUBLISHED FOR OPPOSITION	
Feb. 20, 2019	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	
Jan. 31, 2019	APPROVED FOR PUB - PRINCIPAL REGISTER	
Jan. 24, 2019	ASSIGNED TO EXAMINER	91238
Oct. 25, 2018	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	
Oct. 18, 2018	NEW APPLICATION ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: PUBLICATION AND ISSUE SECTION

Date in Location: May 28, 2019

Generated on: This page was generated by TSDR on 2019-08-28 10:10:22 EDT

Mark: NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES

US Serial Number: 75783702

Application Filing Date: Aug. 24, 1999

US Registration Number: 2691306

Registration Date: Feb. 25, 2003

Register: Principal

Mark Type: Trademark

Status: The registration has been renewed.

Status Date: Mar. 05, 2013

Publication Date: Apr. 25, 2000

Notice of Allowance Date: Jul. 18, 2000

Mark Information

Mark Literal Elements: NEUROCRINE BIOSCIENCES

Standard Character Claim: Yes. The mark consists of standard characters without claim to any particular font style, size, or color.

Mark Drawing Type: 4 - STANDARD CHARACTER MARK

Disclaimer: "BIOSCIENCES"

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis (..) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: pharmaceutical preparations for the treatment of [cancer and] neurological, endocrinological, and central nervous system disorders and diseases

International Class(es): 005 - Primary Class

U.S Class(es): 006, 018, 044, 046, 051, 052

Class Status: ACTIVE

Basis: 1(a)

First Use: Jun. 05, 2001

Use in Commerce: Jun. 05, 2001

Basis Information (Case Level)

Filed Use: No

Currently Use: Yes

Amended Use: No

Filed ITU: Yes

Currently ITU: No

Amended ITU: No

Filed 44D: No

Currently 44D: No

Amended 44D: No

Filed 44E: No

Currently 44E: No

Amended 44E: No

Filed 66A: No

Currently 66A: No

Filed No Basis: No

Currently No Basis: No

Current Owner(s) Information

Owner Name: Neurocrine Biosciences, Inc.

Owner Address: 12780 El Camino Real
San Diego, CALIFORNIA 92130
UNITED STATES

Legal Entity Type: CORPORATION

State or Country: DELAWARE

Where Organized:

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Allison Strickland Ricketts

Docket Number: NEUB 1809409

Correspondent

Correspondent Name/Address: Allison Strickland Ricketts
Fross Zelnick Lehrman & Zissu, P.C.
151 W. 42nd Street, 17th Floor
New York, NEW YORK 10036
UNITED STATES

Phone: 2128135900

Correspondent e-mail: Ricketts-pr@fzlz.com Ricketts-Docket@fzlz.com

Correspondent e-mail Authorized: Yes

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
Aug. 06, 2019	AMENDMENT UNDER SECTION 7 - ISSUED	71378
Aug. 02, 2019	CASE ASSIGNED TO POST REGISTRATION PARALEGAL	71378
Jul. 05, 2019	TEAS SECTION 7 REQUEST RECEIVED	
Oct. 12, 2018	ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED	
Oct. 12, 2018	TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED	
Aug. 12, 2014	TEAS CHANGE OF CORRESPONDENCE RECEIVED	
Mar. 05, 2013	NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED	
Mar. 05, 2013	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	66607
Mar. 05, 2013	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	66607
Mar. 05, 2013	CASE ASSIGNED TO POST REGISTRATION PARALEGAL	66607
Feb. 21, 2013	TEAS SECTION 8 & 9 RECEIVED	
May 24, 2008	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	73376
May 21, 2008	ASSIGNED TO PARALEGAL	73376
May 05, 2008	TEAS SECTION 8 & 15 RECEIVED	
Apr. 14, 2008	CASE FILE IN TICRS	
Dec. 29, 2006	TEAS CHANGE OF CORRESPONDENCE RECEIVED	
Feb. 25, 2003	REGISTERED-PRINCIPAL REGISTER	
Dec. 17, 2002	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED	
Dec. 13, 2002	ASSIGNED TO EXAMINER	68792
Dec. 10, 2002	STATEMENT OF USE PROCESSING COMPLETE	
Jul. 16, 2002	USE AMENDMENT FILED	
Jul. 16, 2002	TEAS STATEMENT OF USE RECEIVED	
Apr. 15, 2002	PAPER RECEIVED	
Dec. 12, 2001	EXTENSION 3 GRANTED	
Nov. 27, 2001	EXTENSION 3 FILED	
Jul. 17, 2001	EXTENSION 2 GRANTED	
Jul. 17, 2001	EXTENSION 2 FILED	
Mar. 12, 2001	EXTENSION 1 GRANTED	
Jan. 18, 2001	EXTENSION 1 FILED	
Jul. 18, 2000	NOA MAILED - SOU REQUIRED FROM APPLICANT	
Apr. 25, 2000	PUBLISHED FOR OPPOSITION	
Mar. 24, 2000	NOTICE OF PUBLICATION	
Dec. 20, 1999	APPROVED FOR PUB - PRINCIPAL REGISTER	
Dec. 14, 1999	EXAMINER'S AMENDMENT MAILED	
Dec. 03, 1999	ASSIGNED TO EXAMINER	76581

Maintenance Filings or Post Registration Information

Affidavit of Continued Use: Section 8 - Accepted

Affidavit of Incontestability: Section 15 - Accepted

Renewal Date: Feb. 25, 2013

Change in Registration: Yes

Amendment to a Registration/Renewal Certificate: In the statement, Column 1, lines 1-2, "CALIFOR-NIA" should be deleted, and "DELAWARE" is inserted, And, In the statement, Column 1, line 6, "OF CANCER" is deleted, And, the standard character claim is inserted.

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: TMO LAW OFFICE 115

Date in Location: Aug. 06, 2019

Generated on: This page was generated by TSDR on 2019-08-28 10:10:43 EDT

Mark: NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES

US Serial Number: 75783701

Application Filing Date: Aug. 24, 1999

US Registration Number: 2669550

Registration Date: Dec. 31, 2002

Register: Principal

Mark Type: Service Mark

Status: The registration has been renewed.

Status Date: Jan. 09, 2013

Publication Date: Jun. 27, 2000

Notice of Allowance Date: Sep. 19, 2000

Mark Information

Mark Literal Elements: NEUROCRINE BIOSCIENCES

Standard Character Claim: No

Mark Drawing Type: 1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)

Disclaimer: "BIOSCIENCES"

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((.)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: research and development services in the field of pharmaceuticals and treatments for cancer and neurological, endocrinological, and central nervous system disorders and diseases

International Class(es): 042 - Primary Class

U.S Class(es): 100, 101

Class Status: ACTIVE

Basis: 1(a)

First Use: Jan. 1995

Use in Commerce: Jan. 1995

Basis Information (Case Level)

Filed Use: No

Currently Use: Yes

Amended Use: No

Filed ITU: Yes

Currently ITU: No

Amended ITU: No

Filed 44D: No

Currently 44D: No

Amended 44D: No

Filed 44E: No

Currently 44E: No

Amended 44E: No

Filed 66A: No

Currently 66A: No

Filed No Basis: No

Currently No Basis: No

Current Owner(s) Information

Owner Name: Neurocrine Biosciences, Inc.

Owner Address: 12790 El Camino Real
San Diego, CALIFORNIA 92130
UNITED STATES

Legal Entity Type: CORPORATION

State or Country: DELAWARE

Where Organized:

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Allison Strickland Ricketts

Docket Number: NEUB 1809409

Correspondent

Correspondent Name/Address: Allison Strickland Ricketts
Fross Zelnick Lehrman & Zissu, P.C.
4 Times Square, 17th Floor
New York, NEW YORK 10036
UNITED STATES

Phone: 212-813-5967

Correspondent e-mail: ricketts-docket@fzlz.com

Correspondent e-mail Authorized: Yes

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
Oct. 12, 2018	ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED	
Oct. 12, 2018	TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED	
Aug. 12, 2014	TEAS CHANGE OF CORRESPONDENCE RECEIVED	
Jan. 09, 2013	NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED	
Jan. 09, 2013	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	77315
Jan. 09, 2013	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	77315
Jan. 09, 2013	CASE ASSIGNED TO POST REGISTRATION PARALEGAL	77315
Dec. 12, 2012	TEAS SECTION 8 & 9 RECEIVED	
May 16, 2008	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	77315
May 16, 2008	ASSIGNED TO PARALEGAL	77315
Apr. 30, 2008	TEAS SECTION 8 & 15 RECEIVED	
Mar. 06, 2008	CASE FILE IN TICRS	
Dec. 29, 2006	TEAS CHANGE OF CORRESPONDENCE RECEIVED	
Dec. 31, 2002	REGISTERED-PRINCIPAL REGISTER	
Oct. 23, 2002	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED	
Oct. 07, 2002	ASSIGNED TO EXAMINER	75590
Oct. 04, 2002	STATEMENT OF USE PROCESSING COMPLETE	
Sep. 18, 2002	USE AMENDMENT FILED	
Sep. 18, 2002	TEAS STATEMENT OF USE RECEIVED	
Sep. 18, 2002	TEAS EXTENSION RECEIVED	
Apr. 15, 2002	PAPER RECEIVED	
Mar. 19, 2002	EXTENSION 3 GRANTED	
Mar. 06, 2002	EXTENSION 3 FILED	
Oct. 12, 2001	EXTENSION 2 GRANTED	
Sep. 18, 2001	EXTENSION 2 FILED	
Apr. 12, 2001	EXTENSION 1 GRANTED	
Mar. 14, 2001	EXTENSION 1 FILED	
Sep. 19, 2000	NOA MAILED - SOU REQUIRED FROM APPLICANT	
Jun. 27, 2000	PUBLISHED FOR OPPOSITION	
May 26, 2000	NOTICE OF PUBLICATION	
Mar. 28, 2000	APPROVED FOR PUB - PRINCIPAL REGISTER	
Feb. 08, 2000	CORRESPONDENCE RECEIVED IN LAW OFFICE	
Jan. 18, 2000	NON-FINAL ACTION MAILED	
Jan. 13, 2000	ASSIGNED TO EXAMINER	75590

Maintenance Filings or Post Registration Information

Affidavit of Continued Use: Section 8 - Accepted

Affidavit of Incontestability: Section 15 - Accepted

Renewal Date: Dec. 31, 2012

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: GENERIC WEB UPDATE

Date in Location: Jan. 09, 2013